Patient preference for biologic treatments of psoriasis in Japan

• Published in: Journal of dermatology Vol. 46; no. 6; pp. 466 - 477
• Main Authors: Tada, Yayoi, Ishii, Kanako, Kimura, Junko, Hanada, Keigo, Kawaguchi, Isao
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.06.2019; John Wiley and Sons Inc
• Subjects: Autoimmune diseases; biologics; Decision making; discrete choice experiment; Drug dosages; Japan; Nails (Anatomy); Original; patient preference; Patient satisfaction; Physicians; Preferences; Psoriasis; Skin diseases; Japan; discrete choice experiment; patient preference; biologics; Japan; psoriasis
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.14870

Psoriasis is a chronic autoimmune disease affecting skin which may also manifest in nails and joints. Several biologic treatments have been approved in Japan for psoriasis. Each biologic has a different profile for efficacy and safety, including different dosing regimens and co‐payment considerations which may complicate treatment decisions made by patients and physicians during short consultations. Elucidating patient preference is expected to contribute to shared decision‐making between patients and physicians to optimize treatment satisfaction and outcomes. However, the number of studies investigating this in Japan is very limited. The study used a discrete choice experiment methodology to elicit patient preferences for hypothetical options in an experimental framework. Participants were asked to choose their preferred treatment option from two hypothetical choices, defined by different levels of six attributes (i.e. early onset of efficacy, long‐term efficacy, sustained efficacy after drug withdrawal, dosing convenience, co‐payment and risk of serious infection). The survey included 16 treatment choice scenarios and was completed by 395 participants. Across all participants, the attribute regarded as most important was sustained efficacy after drug withdrawal, followed by dosing convenience, co‐payment, long‐term efficacy, early onset of efficacy and risk of serious infection. The study found that patients prefer treatments which have durable efficacy and lower treatment burden characterized as fewer injection frequency and lower co‐payment. These results may be helpful to understand patient preference for biologic treatments used for psoriasis in Japan and contribute to shared decision‐making between patients and physicians to improve patient satisfaction and treatment outcomes.